|
Monterey, Calif., April 17, 2008 - An optimized PARI eFlow platform nebulizer will be
delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has
begun enrolling patients. ALN-RSV01 is a RNAi therapeutic being developed
as a treatment for respiratory syncytial virus (RSV) infection, the leading
cause of pediatric hospitalization in the U.S. and a prevalent infection
in immune-compromised adults. RSV currently does not have a viable
treatment option.
"The
progression into Phase II clinical trials with Alnylam's therapeutic is
significant as it is the first RNAi program in clinical trials using
inhalation. We are seeing a number of companies turn to advanced
nebulization with our eFlow platform, because the flexibility allows the
development of new respiratory therapies that are delivered to the lungs in
a faster, more effective manner," said Geoff A. Hunziker, President of
eFlow LLC.
Respiratory
syncytial virus (RSV) is a highly contagious virus that causes infections
in the upper and lower respiratory tract associated with predictable
seasonal outbreaks worldwide. RSV infection is the most common cause for
infant hospitalization (more than 100,000 hospitalizations annually in the U.S.), and
the virus is a significant pathogen in the elderly. The RNAi therapeutic
agent ALN-RSV01 is a small interfering ribonucleic acid (siRNA) targeting
the messenger RNA of the RSV N gene to prevent viral replication. To
deliver ALN-RSV01 to the site of infection, the RNA therapeutic is being
administered as an aerosol in a highly efficient pulmonary delivery system,
an optimized eFlow platform nebulizer, with high drug output, optimized
droplet size, and low residual drug loss.
For
more information on the Phase II study, visit www.alnylam.com.
About eFlow
eFlow, an
electronic, portable nebulizer platform, enables extremely efficient
aerosolization of liquid medications via a vibrating, perforated membrane.
Compared to other nebulizer systems, eFlow can produce aerosols with a very
high density of active drug, a precisely defined droplet size, and a high
proportion of respirable droplets delivered in the shortest possible amount
of time. Combined with its silent mode of operation, small size (it fits in
the palm of your hand), light weight, and battery use, eFlow helps reduce
the burden of taking daily inhaled treatments.
About PARI Pharma
PARI
Pharma develops aerosol delivery devices and inhaled therapies. Based on
PARI's 100-year history working with aerosols, PARI Pharma specializes in
treatments for pulmonary and nasal administration optimized to advanced
delivery platforms, such as eFlow.
Focusing
on comprehensive inhalation therapy development, including optimized
nebulizer formulations, analytics, and aerosol characterization, PARI
Pharma has several clinical development programs ongoing, either partnered
or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany,
with a major presence in the United States.
###
|
